228 related articles for article (PubMed ID: 26037113)
1. Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.
Lee TT; Chana G; Gorry PR; Ellett A; Bousman CA; Churchill MJ; Gray LR; Everall IP
J Neurovirol; 2015 Oct; 21(5):535-43. PubMed ID: 26037113
[TBL] [Abstract][Full Text] [Related]
2. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
Detrait ER; Carr GV; Weinberger DR; Lamberty Y
Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
[TBL] [Abstract][Full Text] [Related]
3. Differential COMT expression and behavioral effects of COMT inhibition in male and female Wistar and alcohol preferring rats.
McCane AM; DeLory MJ; Timm MM; Janetsian-Fritz SS; Lapish CC; Czachowski CL
Alcohol; 2018 Mar; 67():15-22. PubMed ID: 29310047
[TBL] [Abstract][Full Text] [Related]
4. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.
Maser T; Rich M; Hayes D; Zhao P; Nagulapally AB; Bond J; Saulnier Sholler G
Cancer Med; 2017 Jun; 6(6):1341-1352. PubMed ID: 28429453
[TBL] [Abstract][Full Text] [Related]
5. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
6. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.
Giakoumaki SG; Roussos P; Bitsios P
Neuropsychopharmacology; 2008 Dec; 33(13):3058-68. PubMed ID: 18536698
[TBL] [Abstract][Full Text] [Related]
7. Genotype-Dependent Effects of COMT Inhibition on Cognitive Function in a Highly Specific, Novel Mouse Model of Altered COMT Activity.
Barkus C; Korn C; Stumpenhorst K; Laatikainen LM; Ballard D; Lee S; Sharp T; Harrison PJ; Bannerman DM; Weinberger DR; Chen J; Tunbridge EM
Neuropsychopharmacology; 2016 Dec; 41(13):3060-3069. PubMed ID: 27388330
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
Vieira-Coelho MA; Soares-da-Silva P
Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
[TBL] [Abstract][Full Text] [Related]
10. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
[TBL] [Abstract][Full Text] [Related]
11. Catechol-O-Methyltransferase inhibition and alcohol use disorder: Evaluating the efficacy of tolcapone in ethanol-dependent rats.
Doyle MR; Dirik S; Martinez AR; Hughes TE; Iyer MR; Sneddon EA; Seo H; Cohen SM; de Guglielmo G
Neuropharmacology; 2024 Jan; 242():109770. PubMed ID: 37858886
[TBL] [Abstract][Full Text] [Related]
12. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.
Boehn SN; Spahn S; Neudecker S; Keppler A; Bihoreau MT; Kränzlin B; Pandey P; Hoffmann SC; Li L; Torres VE; Gröne HJ; Gretz N
Nephrol Dial Transplant; 2013 Aug; 28(8):2045-58. PubMed ID: 23543593
[TBL] [Abstract][Full Text] [Related]
15. Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development.
Chen J; Song J; Yuan P; Tian Q; Ji Y; Ren-Patterson R; Liu G; Sei Y; Weinberger DR
J Biol Chem; 2011 Oct; 286(40):34752-60. PubMed ID: 21846718
[TBL] [Abstract][Full Text] [Related]
16. Dopamine, locus of control, and the exploration-exploitation tradeoff.
Kayser AS; Mitchell JM; Weinstein D; Frank MJ
Neuropsychopharmacology; 2015 Jan; 40(2):454-62. PubMed ID: 25074639
[TBL] [Abstract][Full Text] [Related]
17. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism.
Roussos P; Giakoumaki SG; Bitsios P
Biol Psychiatry; 2009 Dec; 66(11):997-1004. PubMed ID: 19699472
[TBL] [Abstract][Full Text] [Related]
18. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
Vieira-Coelho MA; Soares-da-Silva P
Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
[TBL] [Abstract][Full Text] [Related]
19. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation.
Grant JE; Odlaug BL; Chamberlain SR; Hampshire A; Schreiber LR; Kim SW
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1587-96. PubMed ID: 23953269
[TBL] [Abstract][Full Text] [Related]
20. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
